A BMC Primary Care study estimates the substantial costs of long-COVID management in non-hospitalized UK patients, revealing higher expenses for patients with diagnosed long-COVID, older adults, women, obese individuals, and those with comorbidities.
Bristol immunotherapy improves responses in lung cancer, setting up Phase 3 study
BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint inhibitor and chemotherapy improved responses for certain patients with a